logo

Momenta Pharmaceuticals Inc (MNTA)



Trade MNTA now with
  Date
  Headline
1/13/2020 7:53:08 AM Momenta Expects 2020 Non-GAAP Operating Expense Of $220 Mln-240 Mln
1/3/2020 8:06:36 AM Momenta Pharmaceuticals Names Young Kwon CFO Effective January 8, 2020
12/13/2019 8:06:56 AM Momenta Pharmaceuticals Appoints Jane Barlow To Board
8/2/2019 7:14:42 AM Momenta Pharma Q2 Total Revenue $5.2 Mln Vs $13.0 Mln Last Year
6/19/2019 8:14:27 AM Momenta, Sandoz AG, Amphastar Enter Mutually Agreeable Settlement Agreement
2/22/2019 6:45:14 AM Momenta Pharma Q4 Net Loss $8.2 Mln Or $0.10/Shr Vs Income Of $13.8 Mln Or $0.18/Shr Last Year
1/29/2019 8:05:42 AM Momenta Pharma Announces First Subject Dosed In Phase 1/2 Clinical Trial Of M254, Hypersialylated Immunoglobulin G
12/5/2018 4:20:35 PM Momenta Pharmaceuticals Announces Proposed Public Offering Of Common Stock
11/7/2018 6:09:41 AM Momenta Pharma Q3 Net Loss $50.3 Mln Or $0.65/shr Vs. Net Loss $33.2 Mln Or $0.44/shr Last Year
10/1/2018 6:06:12 AM Momenta To Streamline Operations Through Corporate Restructuring
8/9/2018 6:06:02 AM Momenta Pharma Q2 Net Loss $69.9 Mln Or $0.91/Shr Vs Loss Of $36.9 Mln Or $0.50/Shr Last Year
5/8/2018 7:10:30 AM Momenta Pharma Q1 Net Loss $47.6 Mln Or $0.63/Shr Vs Loss Of $31.8 Mln Or $0.46/Shr Last Year
2/21/2018 8:06:12 AM Momenta Pharma Q4 Total Revenues $64.6 Mln Vs. $34.2 Mln Prior Year
2/13/2018 1:18:32 AM Momenta Pharma Announces FDA Approval And Launch Of Glatopa (glatiramer Acetate Injection) 40 Mg/mL
1/30/2018 8:21:18 AM Momenta Pharma Announces Positive Outcome For Contracted Glatopa Fill/Finish Manufacturer
  
 
>